Sector News

Shire steps away from biosimilars

September 29, 2016
Life sciences

Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases.

The UK-based group is returning global development and commercialisation rights to M923, a proposed biosimilar of Humira (adalimumab), to US group Momenta Pharmaceuticals, but will continue to fund the programme for 12 months as per the original deal with Baxalta.

“We view Shire’s decision as a significant opportunity for us to capture additional value from this program for the Company and its shareholders. We remain very excited about the potential for our biosimilar HUMIRA candidate and look forward to reporting top-line results of the current Phase III trial of M923 in late 2016,” said Momenta’s president and chief executive, commenting on the move.

US biotech Coherus BioSciences has also regained from Shire all development and commercial rights previously licensed for CHS-0214 etanercept, a biosimilar candidate to Enbrel, for Europe, Canada, Brazil, the Middle East and other territories.

The drug has successfully completed two Phase III studies, in chronic plaque psoriasis and rheumatoid arthritis, data from which will support its European marketing application, planned for the fourth quarter of this year.

“These reacquired geographical rights fit well with our existing US CHS-0214 rights, and we now have the opportunity to license throughout Europe, US and other key commercial geographies two complimentary Anti-TNF assets – CHS-0214, an Enbrel biosimilar candidate and CHS-1420, a Humira biosimilar candidate”.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”